Meet the team ready to see human and scientific potential realized
Strong team of experts in virology, plant-expression and medicine
We’re a team of future-minded individuals working to make the world a healthier place.
Chief Executive Officer
Hugh is founder and CEO of KBP, having built the company into one of the leading plant-based producers of vaccines and biopharmaceuticals. In 2014, he lead KBP’s involvement in a rapid response to the Ebola pandemic. In addition, Hugh negotiated and executed more than $2 billion in financing transactions as a state commissioner for economic development.
Dr. Hutan Ashrafian
Chief Medical Officer, BAT Group
Dr. Ashrafian is a senior clinician and surgeon and holds an MD, PhD in Computational Physiology and Metabolic Surgery. He holds an MBA (with Distinction) and Arris and Gale lectureship at Royal College of Surgeons. He has been published in a variety of leading journals including Nature, The Lancet and The New England Journal of Medicine.
Dr. Gregory Pogue
Dr. Pogue is an expert in virology and molecular biology. He has held VP or above roles in six startups; one IPO’d on NASDAQ, a second acquired by a Fortune 500 company, and three obtained large licensing deals. He is a former FDA reviewer and has published more than 60 scientific articles and issued more than 35 patents.
Director of Operations
Barry was a co-founder of KBP and has been Director of Operations since its inception. He has over 30 years of experience developing and running cGMP processes for expressing and purifying recombinant proteins and plants. He oversaw the 2014-2016 execution of over 60 consecutive cGMP runs of the zMapp anti-Ebola monoclonal antibody.
Head of Process Development
Joshua is a protein biochemist with over 20 years of pharmaceutical experience. He drove product and facility launches of recombinant insulin analogues at Eli Lilly and Company. He holds graduate degrees in Biochemistry/Biotechnology from John Hopkins University.
Dr. Carrie Simpson
Quality Control Lead
Dr. Simpson holds a Ph.D. in Analytical Chemistry with a focus on nano chemistry and vaccines. She was awarded a post-doc fellowship from the Bill & Melinda Gates Foundation where she worked on nano-chemistry based TB vaccinations. In addition, she spent three years teaching chemistry as a university faculty member.
Quality Assurance Lead
Katrina has over two decades of experience in pharmaceutical quality assurance. She’s developed and maintained many of the systems used for quality assurance in KBP, including those deployed as part of the 2014-2016 cGMP zMapp Ebola response efforts.
Striving to be at the forefront of global health efforts
We have a vision to become a world leader in plant-based biologics. Discover our story and how we are working to pave the way for a better tomorrow using our plant-based platform and innovative technologies. BAT-owned KBP is located in Owensboro, Ky., where it began operations in 2006. In January 2014, KBP was acquired by and became an independently operated, wholly-owned subsidiary of Reynolds American Inc. (RAI), owned by BAT.
Produced an anti-Ebola monoclonal antibody cocktail ZMappTM in partnership with MappBio. Went from project start to clinical drug substance in under 6 weeks.
Promising pre-clinical evidence showing the potential for our vaccine platform in pandemic Flu (Mallajosyula, Jyothi K., et al. 2014).
Produced a monoclonal antibody intended to block sexual transmission of genital herpes and HIV for Phase I trials in collaboration with MappBio (MB66).
Entered Phase I clinical trials with our investigational Quadrivalent Flu vaccine candidate.
Entered Phase I clinical trials with our investigational COVID vaccine candidate.